TORONTO, Feb. 12,
2024 /CNW/ - Neighbourly Pharmacy Inc.
("Neighbourly" or the "Company") (TSX: NBLY),
Canada's largest and fastest
growing network of independent pharmacies, announced today that it
has filed and is in the process of mailing the management
information circular (the "Circular") and related
materials in connection with the special meeting (the
"Meeting") of its shareholders (the "Shareholders")
to be held virtually on March 8,
2024. The Meeting has been called for the Shareholders to
consider and, if deemed advisable, to pass a special resolution
(the "Arrangement Resolution") approving a previously
announced statutory plan of arrangement involving the Company and
T.I.D. Acquisition Corp. (the "Purchaser"), a newly-formed
entity controlled by Persistence Capital Partners ("PCP"),
pursuant to which the Purchaser will acquire all of the issued and
outstanding common shares (the "Common Shares") in
the capital of the Company, other than those Common Shares already
owned by PCP or its affiliates, for $18.50 per Common Share in cash (the "Cash
Consideration") plus one contingent value right ("CVR"
and collectively with the Cash Consideration, the
"Consideration") per Common Share, which will entitle the
holder thereof to an additional cash payment of $0.61 per CVR if the Company's Pro-Forma Adjusted
EBITDA for the 2026 fiscal year is at or above $128.0 million (the "CVR EBITDA Target"),
the whole subject to the terms and conditions of the arrangement
agreement dated January 15, 2024 (the
"Arrangement Agreement") between the Company and the
Purchaser (the "Arrangement").
Board Recommendation
The board of directors of the Company (the "Board")
having taken into account such factors and matters as it considered
relevant including, among other things, the recommendation of the
independent special committee of the Board (the "Transaction
Committee"), unanimously determined that the Arrangement is in
the best interests of the Company and fair, from a financial point
of view, to the holders of Common Shares (other than PCP and its
affiliates). Accordingly, the Board unanimously recommends that the
Shareholders vote in favour of the Arrangement Resolution at the
Meeting.
Reasons for the Recommendation
In making its recommendation to the Board, the Transaction
Committee considered and relied upon a number of substantive and
procedural factors as set out in the Circular, including, among
others, the following:
- Cash Consideration is an Attractive Premium to
Shareholders. The Cash Consideration offered to Shareholders
under the Arrangement represents a premium of approximately 53% to
the closing price of the Common Shares of $12.12 on the Toronto Stock Exchange
("TSX") on October 2, 2023
(being the last trading day prior to the announcement of the letter
of intent between the Company and PCP), and a premium of
approximately 33% to the 20-day volume weighted average price per
Common Share on the TSX of $13.96,
respectively, as of the end of trading on October 2, 2023.
- Value Supported by the Formal Valuation and Fairness
Opinion. The Transaction Committee's independent financial
advisor, TD Securities Inc. ("TD Securities"), prepared a
formal valuation of the Common Shares and the CVRs in accordance
with Multilateral Instrument 61 101 – Protection of Minority
Security Holders in Special Transactions, concluding that, as
of January 14, 2024, and based upon
and subject to the assumptions, limitations and qualifications set
forth therein, the fair market value of the Common Shares was in
the range of $18.50 to $23.50 per Common Share and the fair market value
of the CVRs was in the range of $0.14
to $0.34 per CVR. In addition, TD
Securities also orally delivered to the Transaction Committee a
fairness opinion that, as of January 14,
2024, and subject to the assumptions, limitations and
qualifications set forth therein, the Consideration to be received
by the Shareholders pursuant to the Arrangement Agreement is fair,
from a financial point of view, to the holders of the Common Shares
(other than PCP and its affiliates).
- Potential Additional Consideration. The Consideration
includes one CVR per Common Share, which provides the holders of
Common Shares (other than PCP and its affiliates) with an
opportunity to receive an additional $0.61 per CVR if the CVR EBITDA Target is
met.
- Transaction Committee Oversight. The Transaction
Committee, which is comprised entirely of independent directors and
was advised by experienced and qualified independent financial and
legal advisors, oversaw, reviewed and considered, and directly
participated in the negotiation of, the Arrangement Agreement.
Interim Order
The Company has been granted an interim order (the "Interim
Order") from the Ontario Superior Court of Justice (Commercial
List) authorizing various matters, including the holding of the
Meeting and the mailing of the Circular.
Meeting and Circular
The Meeting is scheduled to be held as a virtual-only meeting
conducted via live audio webcast at meetnow.global/MS9WCLU on
March 8, 2024 at 10:00 a.m. (Eastern time). It is recommended
that Shareholders join at least fifteen minutes before the start of
the Meeting. The Shareholders, regardless of geographic location,
will have an equal opportunity to participate in the Meeting
online, but will not be able to attend the Meeting in person. The
Shareholders of record as on the close of business on January 29, 2024 are entitled to receive notice
of and vote at the Meeting.
The Arrangement must be approved by at least (i) two-thirds (66
2/3%) of the votes cast by Shareholders virtually
present or represented by proxy at the Meeting, voting as a single
class (each holder of Common Shares being entitled to one vote per
Common Shares) and (ii) the approval of the majority of the
Shareholders virtually present or represented by proxy at Meeting,
excluding the votes of PCP and its affiliates, and any other
Shareholders whose votes are required to be excluded for the
purposes of "minority approval" under Multilateral Instrument
61-101 – Protection of Minority Security Holders in Special
Transactions in the context of a "business combination".
Shareholders may vote prior to the Meeting by completing a form
of proxy or voting information form in accordance with the
instructions provided therein, and delivering the executed form of
proxy to the Company's transfer agent before 10:00 a.m. (Eastern time) on March 6, 2024 (or if the Meeting is adjourned or
postponed, not later than forty eight (48) hours (excluding
Saturdays, Sundays and statutory holidays) prior to the
commencement of the Meeting) (the "Proxy Deadline").
Shareholders are urged to vote well before the Proxy Deadline.
Shareholders may also vote at the Meeting. Registered
Shareholders may vote by completing a ballot online. Details on how
Shareholders who hold Common Shares through a broker, investment
dealer, bank, trust company or other intermediary can attend,
participate or vote at the Meeting are included in the
Circular.
The Circular provides important information on the Arrangement
and related matters, including the background to the Arrangement,
the rationale for the recommendation made by the Transaction
Committee and the Board, voting procedures and how to virtually
attend the Meeting. Shareholders are urged to read the Circular
carefully and in its entirety, and, if assistance is required, to
consult their financial, legal, tax or other professional advisors.
The Circular is being mailed to the Shareholders in compliance with
applicable laws and the Interim Order. The Circular is available on
the SEDAR+ profile of Neighbourly at www.sedarplus.com and
Neighbourly's investor relations website at
https://investors.neighbourlypharmacy.ca/events-and-presentations/default.aspx.
The Arrangement is expected to close on or about March 15, 2024, subject to obtaining the required
Shareholder approval at the Meeting and all other conditions of the
Arrangement being satisfied.
Shareholder Questions and Assistance
Shareholders who have questions about the information contained
in the Circular, or require assistance with the procedure for
voting, including to complete the form of proxy or letter of
transmittal mailed together with the Circular, may contact
Computershare Investor Services Inc., at 1-800-564-6253 (toll free
in Canada and the United States) or 1-514-982-7555 (from
outside of Canada and the United States), or by email at
corporateactions@computershare.com.
Forward Looking Information
This news release contains "forward-looking information"
and "forward-looking statements" (collectively, "forward-looking
information") within the meaning of applicable securities laws.
This information includes, but is not limited to, statements
concerning our objectives, our strategies to achieve those
objectives, as well as statements made with respect to management's
beliefs, plans, estimates, projections and intentions, and similar
statements concerning anticipated future events, results,
circumstances, performance or expectations that are not historical
facts. In some cases, forward-looking information can be identified
by the use of forward-looking terminology such as "expects",
"estimates", "outlook", "forecasts", "projection", "prospects",
"intends", "anticipates", "believes", or variations of such words
and phrases or statements that certain actions, events or results
"may", "could", "would", "might", "will", "will be taken", "occur"
or "be achieved". In addition, any statements that refer to
expectations, intentions, projections or other characterizations
of future events or circumstances contain forward-looking
information. Statements containing forward-looking information
are not historical facts but instead represent management's
expectations, estimates and projections regarding future
events or circumstances. Forward-looking information in this news
release include, among other things, statements relating to
Neighbourly's business in general; and statements relating to the
Meeting, the transaction, the ability to complete the transactions
contemplated by the Arrangement Agreement and the timing thereof,
including the parties' ability to satisfy the conditions to the
consummation of the transaction, the receipt of the required
shareholder approvals and Court approval and other customary
closing conditions, the achievement of the CVR EBITDA Target and
the payout of additional amounts to holders of CVRs under the
Arrangement Agreement, and the expected benefits to the Company and
its shareholders of the proposed transaction.
Risks and uncertainties related to the transactions contemplated
by the Arrangement Agreement include, but are not limited to: the
possibility that the transaction will not be completed on the terms
and conditions, or on the timing, currently contemplated, and that
it may not be completed at all, due to a failure to obtain or
satisfy, in a timely manner or otherwise, required regulatory,
shareholder and Court approvals and other conditions to the closing
of the transaction or for other reasons; the risk that competing
offers or acquisition proposals will be made; the negative impact
that the failure to complete the transaction for any reason could
have on the price of the Common Shares or on the business of the
Company; the failure of PCP to enter into definitive agreements
with respect to the debt commitment or the equity commitment, or
PCP's failure to satisfy the closing conditions thereunder in a
timely manner or at all; the Purchaser's failure to pay the cash
consideration at closing of the transaction; the ability of the
Purchaser to pay any expense fee under the Arrangement Agreement,
should such fee become payable, as its obligations are not
guaranteed; the absence of a reverse break fee in favour of the
Company; the business of Neighbourly may experience significant
disruptions, including loss of clients or employees due to
transaction related uncertainty, industry conditions or other
factors; risks relating to employee retention; the risk of
regulatory changes that may materially impact the business or the
operations of Neighbourly; the risk that legal proceedings may be
instituted against Neighbourly; and risks related to the diversion
of management's attention from Neighbourly's ongoing business
operations while the transaction is pending; and other risks and
uncertainties affecting Neighbourly, including those described in
in the Company's annual information form for the 52-week period
ended March 25, 2023, as well as
other filings and reports Neighbourly may make from time to time
with the Canadian securities authorities.
Although we have attempted to identify important risk factors
that could cause actual results to differ materially from those
contained in forward-looking information, there may be other risk
factors not presently known to us or that we presently believe are
not material that could also cause actual results or future events
to differ materially from those expressed in such forward-looking
information. There can be no assurance that such information will
prove to be accurate, as actual results and future events could
differ materially from those anticipated in such information. No
forward-looking statement is a guarantee of future results.
Accordingly, you should not place undue reliance on forward-looking
information, which speaks only as of the date made. The
forward-looking information contained in this news release
represents the Company's expectations as of the date of this news
release (or as the date they are otherwise stated to be made) and
are subject to change after such date. However, the Company
disclaims any intention or obligation or undertaking to update or
revise any forward-looking information whether as a result of new
information, future events or otherwise, except as required under
applicable securities laws in Canada. All of the forward-looking information
contained in this news release is expressly qualified by the
foregoing cautionary statements.
This announcement is for informational purposes only and does
not constitute an offer to purchase or a solicitation of an offer
to sell, or an offer to sell or a solicitation of an offer to buy,
Neighbourly Common Shares.
About Neighbourly Pharmacy
Inc.
Neighbourly is Canada's largest
and fastest growing network of community
pharmacies. United by their patient first focus and their
role as essential and trusted healthcare hubs within their
communities, Neighbourly's pharmacies strive to provide
accessible healthcare with a personal touch. Since 2015,
Neighbourly has expanded its diversified national
footprint to include 294 locations, reinforcing the
Company's reputation as the industry's acquirer of choice.
SOURCE Neighbourly Pharmacy Inc.